O'Toole David D 4

What Happened

• David D. O'Toole, CFO of AVITA Medical (RCEL), received equity awards on Feb 18, 2026: 105,470 restricted stock units (RSUs) and 155,510 derivative awards (stock options) reported as granted at $0.00. The grants represent compensation awards — not open-market purchases or sales — and showed no cash outlay in the filing.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 19, 2026 (timely filing).
• RSU grant: 105,470 RSUs (reported as acquisition, price N/A); vest in three equal annual installments beginning 12 months after the grant date. (Footnote F1)
• Derivative/option grant: 155,510 awards reported at $0.00 (acquired = $0); these stock options vest in three equal annual installments beginning the first anniversary of the grant date. (Footnote F3)
• Filing notes these awards include unvested RSUs (Footnote F2). The filing does not specify total shares owned by O'Toole after the grants.
• No sale or purchase on the open market was reported; these are compensation grants.

Context

• These awards are time‑based compensation and only convert to vested shares (or become exercisable) over the stated vesting schedules; they do not represent immediate liquidity or a market purchase/sale.
• For retail investors, grants are a routine part of executive compensation and not necessarily a direct bullish signal.